First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $17.3B — +6.0% growth in a single year.
What’s Driving the Stock
1IQVIA's recent partnership with a leading pharmaceutical company to enhance drug development efficiency could drive a 15% increase in contract research revenue.
2Expansion of IQVIA's analytics platform into emerging markets is expected to unlock $500M in new revenue opportunities over the next three years.
3A recent uptick in pharmaceutical R&D budgets, driven by increased demand for innovative therapies, is likely to boost IQVIA's service demand.
4Potential regulatory changes in the EU could streamline drug approval processes, positively impacting IQVIA's contract research services.
5Digital transformation in healthcare
6Increased focus on real-world evidence in drug development
"Management highlighted, 'Our strategic partnerships and innovative solutions position us well to capitalize on the evolving landscape of healthcare.'"
Moat: IQVIA's extensive data assets and established relationships with pharmaceutical companies provide a strong competitive moat.
growth - Investors are likely attracted to IQVIA for its potential to capitalize on the growing demand for data-driven solutions…
Higher interest rates can increase financing costs for pharmaceutical companies…
Watch on earnings: Global pharmaceutical R&D spending growth rate, Adoption rates of digital health solutions, Free cash flow margin.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $17.3B to $18.3B as iqvia's recent partnership with a leading pharmaceutical company to enhance drug development efficiency could drive.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.